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OVERVIEW—Just as treatment guide-
lines for diabetes care were at the fore-
front of medical guideline development
(1), diabetes has been a prominent focus
of performance measurement and quality
improvement initiatives for well over a
decade. However, the constraints of pre-
electronic health records (EHRs) data
systems have consistently limited the
clinical scope and sophistication of cur-
rent diabetes quality measures. The U.S.
health care system is nearing a tipping
point in the use of more sophisticated
EHR-based information systems, and
widespread use of these systems will
usher in a new era for diabetes quality
measurement. New information system
capabilities will enable improvements to
existing measures and enable development
of much more sophisticated measures
that can accommodate personalization
of clinical goals, patient preferences,
and patient-reported data, thus moving
both guidelines and measures toward
personalization based on sophisticated
assessment of the risks and benefits of
certain clinical actions for a given patient
at a given clinical encounter.
To facilitate discussion of the future
of performance measurement in diabetes
in this era of rapid transition to EHRs, the
American Diabetes Association (ADA)
convened a consensus development con-
ference in December 2010. Participating
experts identified and discussed the fol-
lowing questions:
1. What is the evidence that measuring
quality, benchmarking, and provid-
ing feedback or incentives improve
diabetes care?
2. What are the limitations, burdens, and
consequences (intended or unintended)
of diabetes quality measures as cur-
rently structured?
3. What should be the role of shared
decision making, patient preferences,
and patient-reported data in quality
measures?
4. What is the future of quality measure-
ment in diabetes?
5. How can quality monitoring be inte-
grated into population surveillance
efforts?
This report summarizes the consen-
sus meeting, and represents the expert
opinion of its authors and not the official
position of the ADA or any other partici-
pating organization.
1. What is the evidence that
measuring quality, benchmarking,
and providing feedback or
incentives improve diabetes care?
The first national effort to develop a set
of performance measures for diabetes was
convened by the Center for Medicare
andMedicaid Services (CMS), the National
Committee onQuality Assurance (NCQA),
and the ADA in 1995 (2). Evidence showed
that complications of diabetes can be re-
duced by controlling hemoglobin A1c
(A1C), blood pressure, and LDL choles-
terol, but health system performance was
suboptimal and highly variable (2–4). The
Diabetes Quality Improvement Program
(DQIP) groups specified a set of eight pro-
cess and outcomes measures that were
measured at the individual patient level
and aggregated across the patient samples
of health plans, physicians, or other units.
The DQIP measures were specified for use
in the Healthcare Effectiveness Data and
Information Set (HEDIS) measure estab-
lished by NCQA and subsequently widely
adopted for performance assessment in
commercial, Medicare, and Medicaid
health plans. Other health plans and
some government agencies, such as the
Veterans Health Administration (VHA)
and CMS, also adopted the core measure
set for use at physician or group practice
level. Most of the measures were subse-
quently endorsed by the National Quality
Forum (NQF) and are included in pay-
ment programs such as the Physician
Quality Reporting System (PQRS) and
Meaningful Use. Simple processes, such
as periodic testing for A1C, LDL choles-
terol, or microalbuminuria, or periodic
retinal examination, are relatively easy to
identify in eithermedical records or health
care claims. Periodic performance of these
processes is appropriate for nearly all pa-
tients, with the possible exception of very
elderly patients for whom limited life
span may preclude the need to screen
for complications if they have not already
appeared.
During the past decade, the propor-
tion of patients receiving these processes
of care has increased across a range of
settings (5–7). For several measures, in-
cluding A1C, LDL cholesterol, andmicro-
albuminuria testing, proportions are
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approaching 90%, at least in commercial
health maintenance organizations and
Veterans Administration populations.
However, quality of care improvements
with performance measurement does
not seem to generalize to aspects of care
beyond diabetes. For example, the U.S.
Department of Veterans Affairs, which
implemented aggressive measurement
and quality improvement strategies in
the 1990s, has been shown to have better
quality of diabetes care than the private
sector, but has care comparable to the pri-
vate sector in clinical domains without
performance measures (8,9).
Several studies demonstrate that al-
though it is relatively easy to improve
performance for simple processes of care,
improvements in important intermediate
outcomes such as A1C, blood pressure,
and LDL cholesterol do not necessarily
follow (10,11). Some care systems with
intense disease management programs
have improved processes of care but not
necessarily intermediate outcomes (12),
and correlations between system-level
performance for processes of care and
for intermediate outcomes such as risk
factor control are weak (13). This discon-
nect between processes and outcomes of
care raises the question of whether pro-
cess measures are valid indicators of
quality and point to the need to empha-
size intermediate outcomes or to develop
alternative process indicators more closely
linked to intermediate outcomes of care.
Indicators of intermediate outcomes
of care (control of blood pressure, A1C,
and LDL cholesterol) were also among
the original DQIP measures and have
been included in most subsequent diabe-
tes quality measurement sets. Unlike sim-
ple process measures, adequate control of
these risk factors is related to improved
clinical outcomes including cardiovascu-
lar events, microvascular complications,
and mortality. Assuming that safe,
evidence-based treatments are used (14),
it is likely that populations with better
risk factor control or greater improvements
in risk factor control over time are receiving
better quality care and are benefiting clin-
ically. In fact, as process measures and
measures of risk factor control have im-
proved in the U.S., a concomitant reduc-
tion in several major adverse outcomes
(kidney failure, amputation) has been
documented among the population with
diabetes (6,15–17).
Are these measureable improvements
due, at least in part, to initiatives related
to performance measurement, quality
assessment, and quality improvement? A
number of small randomized controlled
trials of performance measurement sug-
gest that measurement and feedback can
lead to improvements in some quality in-
dicators. This effect is more evident with
process measures than with risk factor
control, and observed improvements gen-
erally wane over time, especially once
feedback ceases (18). Pay for Performance
(PfP) initiatives have been implemented
in multiple systems, and their effect on
quality of care remains controversial.
(19,20) “Real world” data suggest that
the aggressive U.K. PfP initiative markedly
improved control of glucose and choles-
terol for several years after its imple-
mentation (21). However, once targets
were reached, further improvements in
quality of diabetes care slowed, and qual-
ity of care for conditions with no incen-
tives declined. In the Kaiser Permanente
system, financial incentives for diabetic
retinopathy screening increased screening
rates modestly from 85 to 88%. However,
when financial incentives and other care
supports were removed, retinopathy
screening rates fell by 3% per year to
levels below baseline (80%) (22). In a
cluster-randomized trial, incentives and
feedback linked to EHR-based diabetes
clinical decision support modestly im-
proved glucose and blood pressure con-
trol, but effects waned after incentives and
feedback were removed, even though the
clinical decision support continued (23).
In summary, various combinations
of performance measurement, feedback
to clinicians, quality improvement pro-
grams, public reporting, and financial
incentives have been associated with sus-
tained improvements in some aspects
of diabetes care in many settings. These
strategies tend to change specific aspects
of care that are being measured and/or
paid for, and improvements, which are
difficult to maintain, do not necessarily
extend to other aspects of care.
2. What are the limitations, burdens,
and consequences (intended or
unintended) of diabetes quality
measures as currently structured?
Dichotomous quality measures based
on thresholds for continuous variables.
Research now demonstrates that sole re-
liance on measuring and reporting simple
processes is unlikely to have a substantial
impact on patient outcomes, and improve-
ment in process measures can no longer be
taken as evidence that quality of care has
improved (24). Performance measures
based on control of risk factors such as
A1C, blood pressure, and LDL cholesterol
are appealing because these risk factors
predict clinical outcomes, but this ap-
proach presents measurement complexi-
ties and challenges. Control of these risk
factors is influenced not only by provider
actions, but also by factors such as patient
behaviors, comorbidity, and concerns
about medication safety and cost. Current
performance measures identify thresholds
for A1C, blood pressure, and LDL choles-
terol control and usually dichotomized
performance measures based on these
threshold levels. The use of thresholds is
easily understood and simple to report,
but selection of an appropriate threshold
is difficult, especially in the light of recent
clinical trial results and subsequent guide-
line recommendations to individualize
clinical goals for A1C and blood pressure
(25–29).
Dichotomous threshold-based mea-
sures suggest that all patients above the
threshold need additional pharmaco-
logic or lifestyle intervention. Setting high
threshold goals (such as A1C,9%, or sys-
tolic blood pressure [sBP] ,160 mmHg)
reduces poor quality care and can be ap-
propriately applied to all patients eligible
for the measure. However, in most care
systems, only a small fraction of patients
will fail to meet such a high threshold. As
threshold goals are lowered, an increasing
proportion of patients require additional
treatment to reach the more stringent
threshold goals. However, the marginal
benefits of increased treatment diminish
as patients approach the goal, while the
likelihood of treatment-related side effects
and costs of treatment typically increase.
If the risks associated with more in-
tensive treatment are substantive, then
setting low thresholds for accountability
measures (such as A1C,7% or sBP,130
mmHg) may actually do more harm than
good for many patients—clearly an unde-
sirable situation (30). Lack of benefit or
unintended harm is possible, especially
for those above the accountability thresh-
old but already on high dose therapy,
those with terminal illness or limited life
expectancy, and those susceptible to seri-
ous side effects of aggressive therapy such
as hypoglycemia or hypotension (31–34).
In the past, some guidelines have adopted
blood pressure or A1C goals more strin-
gent than those validated in clinical trials
(25,35). While low blood pressure or A1C
levels may benefit some subsets of pa-
tients, incorporating low threshold goals
in accountability measures is problematic
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(36). Finally, aiming for stringent targets
in every patient ignores patient prefer-
ences (37).
Since 2008, many diabetes clinical
guidelines recommend individualization
of A1C and blood pressure goals. In re-
sponse, some quality measures now in-
clude a complex set of exemptions and
exclusions thatmay remain challenging to
implement even when EHRs data are
available. Alternative approaches dis-
cussed below are to increase the ac-
countability threshold to a value that is
appropriated for nearly all patients, to
move from goal-based to risk-based
measures, or to implement new “clinical
action” measures, which are more tightly
linked to outcomes than some current
measures.
Composite diabetes quality measures.
Composite performance scores have been
widely adopted and may improve the re-
liability of performance measurement and
ranking compared with single measures
(38–40). However, various approaches
to combining indicators (averaging by in-
dicator, averaging by patient, or simply
measuring all indicators across all pa-
tients) may yield somewhat different
rankings (41). Composite measures con-
vey less granular clinical information and
should be supplemented by providing
individual measure data to the physicians.
Current composite scores typically weight
each indicator equally, so that simple pro-
cess measures contribute as much to the
score as having risk factors in control.
This problem can be remedied by weight-
ing the components of a composite mea-
sure based on clinical importance.
One variant of the composite score is
the “all-or-none” score, which is the pro-
portion of patients for whom all of a set
of process indicators are met. It has been
suggested that the all-or-nothing ap-
proach is the best way to drive toward
excellence (42). However, because the
score reduces a set of indicators to a sin-
gle dichotomous score for each patient,
all-or-none measures discard a large
amount of information. Consequently
they lack sensitivity for distinguishing
between plans or physicians and tend
to have poor reliability (41). All-or-none
measures may be more useful for
evaluating a multistep process (e.g., diag-
nosing and treating pneumonia), in
which each step is necessary to achieve a
successful outcome. They have less to
offer in assessing or improving the paral-
lel and often independent processes of
diabetes care, especially since not all
care components are of equal importance
to individual patients.
3. What should be the role of
shared decision making, patient
preferences, and patient-reported
data in quality measures?
Patient self-management is an essential
aspect of diabetes care and requires health
care systems and providers to actively
support their patients’ “performance.”
Many experts have suggested that clinical
performance measures evaluate how dia-
betes patients are doing—on both pro-
cesses (such as self care and behaviors)
and outcomes (such as health status)
(43). Patient-reported information may
be useful to identify patient preferences
and goals, decision making, action plans
and follow-up, behavioral risk factors,
psychosocial functioning and distress,
self-care behaviors, and to assess specific
aspects of care such as aspirin use, influ-
enza vaccinations, foot examinations, and
comorbid conditions such as depression
(34,44–47).
Patient-reported information could
be derived in part from electronic medi-
cal records, and in part through surveys
or other evolving technologies. Patient-
reported information could also be used
to assess other aspects of care quality, in-
cluding care experiences, care transitions,
continuity of care (47), patient-provider
interactions, as well as some adverse
events, such as hypoglycemic episodes
(48). Patient decisions not to follow pro-
vider advice can be documented and
may provide an opportunity for the pro-
vider to understand the reasons and re-
spond in a mutually satisfactory way.
Health literacy, numeracy, out-of-pocket
costs, and social environment, which may
mediate health disparities by influencing
patient preferences and adherence to
treatment, may serve as case-mix adjust-
ers for quality measures.
The British National Health Service
(NHS) has pioneered the use of patient-
reported outcomes of care by having all
patients undergoing certain elective sur-
geries fill out pre- and postsurgery reports
of their health status, functional status,
and other information. In the U.S., the
HealthOutcomes Survey (HOS) andCon-
sumer Assessment of Healthcare Providers
and Systems (CAHPS) survey include a
number of performance measurements,
functional assessments, and other patient-
reported measures (PRMs). Collecting
PRMs via efficient and user-friendly mo-
dalities (e.g., kiosks, cell phones, Internet,
automated phone systems) may facilitate
use of a standardized set of behavioral
and psychosocial PRMs with high clinical
value that could be incorporated in the
EHR and then be extracted as perfor-
mance measures (49).
Methodological considerations in se-
lecting PRMs that merit further research
include reliability, validity, sensitivity to
change, feasibility, importance to clini-
cians, importance to public health, ac-
tionability, and user friendliness (50).
The National Institutes of Health (NIH)-
funded Patient Reported Outcomes Mea-
surement Information System (PROMIS)
initiative is an important example of the
potential of PRMs. PROMIS uses analytic
techniques such as item response theory
to create and validate very brief measures
that assess a range of symptoms and qual-
ity of life–related issues (51). In summary,
changing technology, including broader
use of EHRs, will likely usher in a new
era in patient-reported performance mea-
sures, which will broaden the scope and
usefulness of existing performance mea-
sure sets (52–54).
4. What is the future of quality
measurement in diabetes?
The advent of EHR technology will open
new options for diabetes quality measure-
ment, as already noted. Several of the new
opportunities that deserve further atten-
tion are highlighted below, and Table 1
briefly outlines some of the advantages
and challenges of selected innovations.
Clinical action measures. One possible
refinement of dichotomous intermediate
outcome measures is the clinical action
measure. Clinical action measures are of
two types: 1) those that combine a thresh-
old measure for an intermediate outcome
with a process of care for those above the
threshold, and 2) those that suggest a
high-benefit evidence-based clinical ac-
tion in certain clinical circumstances
(55,56). Examples of these measures in-
clude prescribing moderate dose statins
to patients with diabetes over age 40
years, or prescribing an ACE-inhibitor
or angiotensin receptor blocker to pa-
tients with albuminuria. Clinical action
measures could take exclusions into ac-
count by removing patients for whom
care may be contraindicated or not ben-
eficial from the denominator (e.g.,
women of childbearing potential, pa-
tients with end-stage renal disease). By
focusing on the clinical treatment (e.g.,
statins) rather than only a threshold in-
termediate outcome value (e.g., LDL
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cholesterol ,100 mg/dL), these meas-
ures are less likely to motivate treatment
with nonevidence-based treatments (e.g.,
ezetimibe) in order to reach a clinical
threshold (14,57).
For example, clinical action measures
may credit the clinician for appropriate
care if 1) the threshold is met (e.g., blood
pressure below the measure threshold),
or 2) the provider takes an appropriate
clinical action (e.g., starting or increasing
the dose of an appropriate medication)
for a patient above threshold, or 3) the
risk factor returns to below the threshold
within a given time frame without changes
in therapy, or 4) the patient has a contra-
indication to further therapy intensifi-
cation (e.g., a very low diastolic blood
pressure) or is already on high-dose ther-
apy despite an elevated risk factor level.
Clinical action measures have several
strengths. They direct attention to patients
most likely to benefit from added ther-
apy, and they point directly to the ap-
propriate treatment rather than just the
risk factor level. Thus, they help providers
do the “right” thing for the right patient.
They also give credit when the appropri-
ate clinical action is to not intensify med-
ications, thereby diminishing the potential
for unintended consequences related to
overtreatment. Finally, they take known
variation in measurement into account by
giving credit for values that return to tar-
get within a specified time period. Be-
cause many clinical action measures
require access to detailed clinical data,
they depend on evolved electronic data
systems (56,58,59).
Weighted quality measures. Some have
expressed concern that threshold-based
performance measures could focus clini-
cian attention inordinately on patients
currently just above the target and away
from those who are further from the target
and may benefit more (60). Others are
concerned that performance thresholds
could also increase health disparities be-
cause vulnerable patients are often further
from control, although one recent study
allays this concern (61). In general, cur-
rent use of threshold measures may dis-
card important information compared
with considering the full distribution of
values in physician or health plan popu-
lations (62).
If an A1C threshold measure for “good
care” is set at 7%, a provider could get full
credit for moving a patient from 7.1 to
6.9%, but no credit for improving control
in another patient from 8.8 to 7.1%, de-
spite the fact that the latter patient’s risk
has been reduced much more than the
former’s (63,64). These concerns and
others may be somewhat allayed by giving
“partial credit” to clinicians or systems
for treatment efforts, even when a patient
does not reach the target.
Credit is assigned based on predicted
clinical benefit gained by moving patients
from prior poor control to a more favor-
able clinical level. This requires specify-
ing a threshold for poor control (e.g., A1C
.8%) above which no credit is given,
and a threshold for good control (e.g.,
A1C ,7%) at which point full credit is
given. Some experts have suggested that
benefits be quantified using quality-
adjusted life-years saved (65). Other
methods to assign partial credit have
also been proposed and deserve careful
consideration (66).
Personalized risk-based quality mea-
sures. The use of risk-based prediction
models can extend the concept of risk
and benefit in performance measurement
by considering each patient’s calculated
risk for an adverse outcome and defin-
ing the benefit a patient is likely to obtain
from a specific clinical action based on the
UK Propective Diabetes Study (UKPDS),
QRISK, Framingham, or other risk en-
gines (67–69). Depending on known evi-
dence, the selected risk engine integrates
age, comorbidity, other risk factors (e.g.,
smoking), and current treatments to pre-
dict the patient’s risk for a poor outcome.
This approach facilitates a patient-specific
performance measurement across the
Table 1—Summary of selected opportunities for new or improved diabetes performance measures based on increasingly sophisticated
electronic data systems and including patient-reported measures
Opportunity for innovation Goal of measure Challenges Examples or prototype
Measures for primary
prevention of diabetes
Reinforce broad efforts to curb the
epidemic of obesity and diabetes
Extends accountability beyond
health care system to
community, schools, and
work sites
Percent of work sites that offer
health risk appraisal and health
coach; percent schools with
healthy food and adequate
physical activity
Measures that include
resource use
Encourage efficient use of limited
resources
Which providers are accountable
for resource use when many
provide care?
Percent of generics used when
generic available; ratio of
resource use to quality of care
Clinical action measures Encourage timely treatments that
are safe and beneficial
Validation of measures needed;
require detailed integrated data
systems
Percent of diabetes patients at
LDL goal or on moderate-dose
statin
Partial credit measures Encourage providers to focus on
patients in the worst control
Developing consensus calibration
for partial credit
NCQA Diabetes Recognition
Program
Adjust quality measures for
patient characteristics
Avoid unintended consequences
of lower pay for providers in
low-SES settings, thus worsening
health care disparities
Identify weighting factors such as
patient health literacy or social
deprivation index. Do not
condone good poor care
HEDIS already adjusted by
insurance type
Patient-reported measures Integrate standard set of measures
within EHR data structures
Measure selection and validation;
efficiency of data collection
CAHPS, NHS, PROMIS
Personalized risk-based
measures
Identify and prioritize clinical
actions of greatest benefit to
patients at encounter
Incomplete evidence base to
assess reversible risk reduction
in all scenarios
Prototype risk engines available
(QRISK, UKPDS, Archimedes,
Framingham, Wizard)
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continuum of benefit and risk. Such
performance measures might assess 1)
whether patients above a certain threshold
of high risk (where benefit of therapy
would clearly outweigh potential harms
of treatment) received the therapy in ques-
tion; 2) whether those below a certain
threshold of low risk (where benefit is
lower than potential harms) did not re-
ceive the therapy; and 3) whether those
in between the two thresholds had a
documented discussion of risk and benefit
of the therapy and engaged in shared or
informed decision making (70). Before
this approach is ready for prime time,
more work needs to be done to assure
that the risk and benefit estimates pro-
vided by the risk engines are accurate
and based on evidence from intervention
trials whenever possible. At present, some
risk engines overestimate benefits by
relying too heavily on epidemiological
rather than clinical trial evidence.
Measures of overtreatment. While the
suggestions outlined above are likely to
maximize appropriate care and minimize
unintended consequences of performance
measures (60,71–76), an additional fruit-
ful area lies in constructing and testing di-
rect measures of potential overtreatment,
inappropriate treatment, or harm (74,77).
Creating and reporting such measures
could serve to counter any pressure to in-
tensify therapy inappropriately in the
name of performance improvement. Such
measures might identify suboptimal prac-
tices such as further intensification of
therapy for patients with low diastolic
blood pressure and moderate sBP levels
(e.g., ,140/65 mmHg); use of glyburide
among the elderly or those with impaired
renal function; falls or episodes of hypo-
glycemia severe enough to require emer-
gency care or hospitalization in patients
on complex glucose-lowering regimens
or insulin; or on high doses of blood pres-
sure medications. Patient-reported data
regarding symptoms and treatment bur-
den may enhance our future ability to
quantify overtreatment or potential harm.
Quality measures for primary preven-
tion of diabetes. Currently, diabetes
quality measures focus on the treatment
of those with diagnosed diabetes. The
Diabetes Prevention Program (DPP) dem-
onstrated that either intensive lifestyle
change leading to 7% weight loss or use
of metformin substantially reduced the
incidence of type 2 diabetes in a diverse
U.S. population with impaired glucose
tolerance (78). Both interventions were
cost-effective from the perspective of the
health system and society as delivered in
the DPP (79), and similar weight loss and
exercise outcomes have been achieved
when the DPP lifestyle intervention is im-
plemented in a much less costly form in
community settings (80). New perfor-
mance measures could be designed to as-
sess 1) appropriate implementation of
diagnostic tests to identify those at high
risk of diabetes; 2) appropriate referral to
lifestyle programs and/or metformin ther-
apy; and 3) relative quality and efficacy
of lifestyle programs designed to achieve
weight loss. Such measures would not
only foster the implementation of proven
interventions of tremendous public health
significance, but would be important
models of measuring community-based
public health initiatives designed to ad-
dress weight management, healthy eating,
and physical activity.
Incorporating measures of adherence
into performance measures. An esti-
mated 20–50% of patients with chronic
disease do not take their medications as
prescribed (81). Poor medication adher-
ence contributes to poor diabetes control,
disability, unnecessary hospitalization,
and death (82,83). A meta-analysis of
63 studies with over 19,000 participants
reported that higher adherence rate de-
creases the risk for poor treatment out-
come by 26% (84). Measures of patient
adherence are impeded by 1) lack of
agreement on the best methods to mea-
sure medication adherence, 2) paucity of
integrated data systems that include both
prescription and medication dispensing
data, and 3) a sparse body of research on
interventions to improve medication ad-
herence (85). As information systems
evolve and more effective interventions
to improve adherence are identified,
quality measures related to medication
adherence may catalyze new efforts to im-
prove adherence and patient health out-
comes.
Incorporating costs into quality mea-
surement. Patients with diabetes gener-
ate medical care costs that are on average
two to three times higher than age- and
gender-matched patients without diabe-
tes. Cardiovascular complications remain
the principal driver of high diabetes care
costs; medication costs are also rising
more rapidly than overall inflation (86–
88). Diabetes and other medical expendi-
tures vary greatly across care systems in
relation to the benefits achieved, and a
substantial portion of expenditures does
not appear to provide any net benefit
to the patient (89). These services are
usually labeled as wasteful, inappropriate,
or inefficient.
NCQA has recently developed diabe-
tes relative resource use measures at
the plan level and is testing them at the
group practice level. These measures are
designed to look at resource use in di-
abetes care and, when combined with
quality measures, can provide an over-
view of efficiency (high resource use–low
quality vs. low resource use–high qual-
ity). Barriers to expanding such measures
include the need for large sample sizes,
the difficulty of accurately quantifying
expenditures, and the need for accurate
risk adjustment. A measure of total ex-
penditures per patient is now available
within the Medicare program and is
based on administrative claims data. The
information can be further categorized
as hospital inpatient, outpatient, or
pharmacy-related (medications). Ex-
penditures can be compared with a set
of outcome-related quality measures as
an initial step toward trying to define the
value (benefit per unit of expenditure) of
care in diabetes.
Over the short term, we need more
analysis and understanding of which ele-
ments of resource use have positive or
negative correlations with measures of
quality and outcomes of care. Currently
most diabetes performancemeasures only
assess whether tests or examinations are
being underused. Development of mea-
sures that look at overuse of tests, exami-
nations, procedures, or technology may
be useful in evaluating and maximizing
efficiency of care. Measures that encour-
age the use of generic medications, when
available, may also conserve resources.
Care provided by various subspecialties
for patients with advanced complications
of diabetes may be variably efficient or
inefficient. With further refinement of
both quality and cost-related measures,
diabetes could become the poster child
for efficient and effective health care.
Using performance measurement to
reduce, not worsen, health disparities.
As with many chronic diseases, diabetes is
marked by disparities in both treatment
and outcomes. Such disparities are pri-
marily based on socioeconomic status
(SES), race, and ethnicity, but also exist
by sex and age. Because patients of lower
SES often have more barriers to self care
and worse control of risk factors, clini-
cians who provide care to many such
patients may have lower quality-of-care
scores publicly reported, or lose income or
incentives related to unadjusted measures
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of clinical performance. Currently, the
HEDIS data are grouped by Medicare,
Medicaid, and commercial insurance.
In the future, quality measures could be
adjusted in more sophisticated ways to
account for variation in patient SES, health
literacy, or other factors related to dispar-
ities in care. Possible methods include
geo-coding, case-mix adjustment, or use
of other metrics for SES. On the other
hand, “overadjusting” for race/ethnicity
and SES could mask real differences in
quality of care provided to different
groups; such disparities can only be cor-
rected if they are identified.
5. How can quality monitoring be
integrated into population
surveillance efforts?
Population surveillance of quality of di-
abetes care provides a crucial complement
to health system monitoring (e.g., HEDIS)
by assessing care in the full population,
including persons with limited or no
health insurance. Appropriately selected
performance measures may serve well as
measures for population-based diabetes
care surveillance and enable more de-
tailed examination of geographic and
other disparities in patterns of care. In
addition, surveillance systems are impor-
tant to monitor risks, adverse events, and
resource use in the population, and to
guide the design and implementation of
strategies to improve quality and outcomes
of care.
Existing population-level monitor-
ing of diabetes care include the National
Health Interview Survey (NHIS); the Be-
havior Risk Factor Surveillance System
(BRFSS), which assesses care processes;
and the National Health and Nutrition
Examination Surveys (NHANES), which
assess both processes of care and risk
factor control. All three of these systems
include extensive PRMs and provide a
useful foundation for further develop-
ment of such PRMs for diabetes care.
Data from these sources also provide
estimates of diabetes care quality that
inform national quality and disparity re-
ports and development of the Healthy
People Objectives for 2010 and 2020.
Other systems such as the National Am-
bulatory Medical Care Survey (NAMCS),
and the National Hospital Discharge Sur-
vey (NHDS) provide additional popula-
tion data on costs and outcomes of care.
With the exception of the Dartmouth
Health Atlas and selected metropolitan
area surveys and laboratory-based regis-
tries in New York and Vermont, there is
limited population-based data in the
U.S. today within smaller geographic areas
(90,91).
Expansion of existing surveillance
systems to include measures of risk fac-
tor control, patient characteristics and
behaviors, risk preferences, indicators of
primary prevention, and other measures
could serve several useful purposes such
as 1) permit more accurate assessment
of care quality for patients at different
levels of risk, insurance, and socioeco-
nomic status and to assess geographic
variations in care; 2) promote monitor-
ing of patient safety, drug safety, costs,
adverse outcomes and unintended conse-
quences (e.g., hypoglycemia and poly-
pharmacy), and medication adherence;
3) prove useful within networks of Patient
Centered Medical Homes or Accountable
Care Organizations; and 4) facilitate sys-
tematic assessment of prevention efforts.
Some of these innovations could be based
on the modification of current population-
based surveys. Others, such as clinical ac-
tion measures, weighted quality measures,
or risk-based quality measures may re-
quire fundamentally new surveillance
systems.
Integration with health system–based
data could augment the depth of public
health systems and extend the represen-
tativeness of health system–based data.
The growing use of EHRs presents an op-
portunity to assess variation in intensity
and quality of diabetes care. Prototypes
for the use of EHRs data for national sur-
veillance include surveillance systems for
vaccine safety, selected infectious disea-
ses, and bioterrorism threats. Diabetes
care surveillance might be carefully ex-
panded in phases, perhaps with a “senti-
nel” system or a distributed data system
as initial steps (92). An essential step is to
develop and validate a common set of
diabetes quality measures. Key data ele-
ments might include laboratory results,
pharmaceutical use, utilization of ser-
vices, and selected patient characteristics
and experiences of care, including ele-
ments collected by patient self-report.
CONCLUSIONS AND
RECOMMENDATIONS—The grow-
ing availability of sophisticated electronic
health data systems will revolutionize
diabetes performance measurement. The
use of a rich set of clinical, patient-
reported, and claims data will strengthen
existing measures and enable develop-
ment and efficient use of new measures
that much more closely mirror the clinical
care of patients, accommodate the need
to customize care based on individual
patient risk and benefit profiles, and in-
corporate assessment of resource use and
patient experience of care. For example,
development of measures that encourage
clinicians to take into account individual
patients’ risk status and the relative bene-
fits of various treatments would support
clinicians’ efforts to make the right deci-
sion for a particular patient while mini-
mizing risk of overtreatment or other
unintended consequences. Wider recog-
nition of the importance of patient pref-
erences is also important, especially when
the clinical benefit associated with clinical
actions is small or uncertain. Several of
the newer approaches to quality measure-
ment outlined here could be implemented
in the near term, while others need
some additional intermediate-term devel-
opment prior to wide-scale dissemination.
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